Figure 4.
ANRIL enhances migration of gastric cancer cells by increasing NF-kB signaling. (a) Knockdown of ANRIL decreases NF-kB signaling; (b) knockdown of ANRIL inhibits migration of MG803 cells in transwell assay, and NF-kB signaling inhibitor sc75741 abolishes the effect; and (c) knockdown of ANRIL inhibits expression of NF-kB target genes. ANRIL: CDKN2B-AS.